An improved route to coenzyme Q 10 (1) starting from commercially available coenzyme Q 1 is described. The key steps in this synthesis are the SeO 2 -mediated oxidation of the protected isoprenylhydroquinone 3 into the (E)-allyl alcohol 5 without the formation of undesired stereoisomer and the one-p
Synthetic Studies on Coenzyme Q10
✍ Scribed by Xiong-Jie Yu; Fen-Er Chen; Hui-Fang Dai; Xu-Xiang Chen; Yun-Yan Kuang; Bin Xie
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- German
- Weight
- 103 KB
- Volume
- 88
- Category
- Article
- ISSN
- 0018-019X
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
A practical, highly stereoselective ten‐step synthesis of coenzyme Q~10~ (1) has been accomplished (overall yield ca. 28%), starting from commercially available 2,3‐dimethoxy‐5‐methylbenzoquinone (Scheme). The introduction of the first side‐chain isoprenyl group with (E)‐configuration (compound 6) was realized by means of a coupling reaction of the aromatic system 3 with oxirane, followed by Swern oxidation and Wittig olefination. The tosyl (Ts) group in the sulfone 9 was selectively removed with sodium naphthalenide in THF to afford 1.
📜 SIMILAR VOLUMES
An efficient and stereoselective approach to the synthesis of coenzyme Q 10 is described (Scheme). The MeOCH 2 -protected p-hydroquinone 4 containing the C 5 (E)-allyl (tert-butyl)dimethylsilyl ether moiety was obtained via a halogen -lithium exchange of the MeOCH 2 -proctected 2-bromo-5,6dimethoxy-
Deuterium-labelled coenzyme Q 10 ([2-CD 3 -1 0 -CD 2 ]coenzyme Q 10 , coenzyme Q 10 -d 5 ) was synthesized by condensation of 2,3-dimethoxy-[5-CD 3 ]methyl-1, 4-hydroquinone with [1-CD 2 ]decaprenol. Five positions were selected for deuteration as replacement at these positions allowed examination o
## Abstract Radio‐labelled coenzyme Q~10~, labelled at the 3′‐position with ^14^C, was synthesized starting from natural solanesol and ethyl [3‐^14^C] acetoacetate. The radiochemical yield was 8.0% from ethyl [3‐^14^C] acetoacetate. The specific radioactivity of the product was 44.8 μCi, 1.66 MBq/m
## Abstract We performed a 6‐month open‐label trial to evaluate the tolerability and efficacy of coenzyme Q10 (CoQ) in 10 patients with Huntington's disease (HD), Subjects were evaluated at baseline, 3 months, and 6 months using the HD Rating Scale (HDRS), the HD Functional Capacity Scale (HDFCS),
We assessed the clinical outcome after coenzyme Q 10 (CoQ 10 ) therapy in 14 patients presenting ataxia classified into two groups according to CoQ 10 values in muscle (deficient or not). We performed an open-label prospective study: patients were evaluated clinically (international cooperative atax